Kodiak Sciences (NASDAQ: KOD)
Key Data Points
Kodiak Sciences Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Kodiak Sciences Company Info
Kodiak's portfolio of candidate eye treatments centers on its innovative antibody biopolymer conjugate platform.
News & Analysis
Why Kodiak Sciences Stock Is Sharply Lower Today
An analyst downgrade is weighing on the drugmaker's stock price today.
Why Kodiak Sciences Stock Is Cratering Today
A disappointing clinical trial result is weighing heavily on the drugmaker's shares today.
Is This Mid-Cap Biotech Stock a Buy Now?
This mid-cap growth stock could be a long-term winner.
Why Kodiak Sciences Stock Is Tumbling Today
The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.
2 Top Healthcare Stocks That Jumped Last Week
Despite recent run-ups, these two have what takes to keep rising.
Billionaires Are Gobbling Up These 3 Healthcare Stocks
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
These Were the 10 Best Stocks of 2019
Seven biotechs led the way.
3 Best Biotech Stocks of 2019: Are They Buys Now?
These stocks have soared 935% or more this year. Can they keep the momentum going?
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.